Schering Corporation and Biogen, Inc. v. Amgen Inc.’s Empirical Analysis
222 F.3d 1347 · 2000
Citation profile
20 federal appellate · 6 district ·
Relationships
Relies on Curtis Publishing Co. v. Butts · Cybor Corporation v. Fas Technologies, Inc., and Fastar Ltd., Defendants-Cross · Amgen, Inc. v. Chugai Pharmaceutical Co. · Nobelpharma AB v. Implant Innovations, Inc. · Litton Systems, Inc. v. Whirlpool Corp.
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 53 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“express intent to impart a novel meaning”
2 later decisions quote this exact passage · from the majority“The fundamental inquiry is whether the material added by amendment was inherently contained in the original application.”
1 later decision quote this exact passage · from the majority“interprets the claim at issue to cover no more than what the specification supported at the time of filing.”
1 later decision quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.